https://doi.org/10.4081/reumatismo.2016.873
New approved drugs for psoriatic arthritis
Submitted: 22 February 2016
Accepted: 13 July 2016
Published: 9 September 2016
Accepted: 13 July 2016
Abstract Views: 2864
PDF: 2130
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
How to Cite
Perrotta, F., & Lubrano, E. (2016). New approved drugs for psoriatic arthritis. Reumatismo, 68(2), 57–64. https://doi.org/10.4081/reumatismo.2016.873
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- V. Bruzzese, J. Pepe, Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab) , Reumatismo: Vol. 61 No. 4 (2009)
- M. Taraborelli, L. Andreoli, S. Archetti, M. Ferrari, R. Cattaneo, A. Tincani, Methylenetetrahydrofolate reductase polymorphisms in methotrexate treatment of rheumatoid arthritis patients. Review of the literature and personal experience , Reumatismo: Vol. 61 No. 2 (2009)
- V. Bruzzese, C. Marrese, P. Scolieri, J. Pepe, Psoriatic spondyloarthritis and Sjögren syndrome: a casual association? , Reumatismo: Vol. 72 No. 3 (2020)
- T. Suzuki, H. Shirai, Subcalcaneal bursitis as the initial manifestation of rheumatoid arthritis: ultrasonographic observation of two cases , Reumatismo: Vol. 71 No. 4 (2019)
- C. Palazzi, I. Olivieri, C. Salvarani, E. D'Amico, G. Alleva, P. Vitullo, A. Petricca, Reactive arthritis: advances in diagnosis and treatment , Reumatismo: Vol. 54 No. 2 (2002)
- C. Sales, F. Oliviero, P. Spinella, Fish oil supplementation in rheumatoid arthritis , Reumatismo: Vol. 60 No. 3 (2008)
- Giuseppe D'Alessandro, Maria Rosaria Bianco, Spiridon Politis, Celestino Ferrandina, Giuseppe Rossi, Emanuele Altomare, Case report: AREB in a patient with rheumatoid arthritis treated with methotrexate and infliximab , Reumatismo: Vol. 58 No. 1 (2006)
- V. Riccieri, A. Spadaro, E. Taccari, A. Zoppini, I. Markus, M. Sesztak, J. Ortutay, E. Koo, Immunohistochemical analysis of the expression of main adhesion molecules and tumor necrosis factors in the synovial membrane of psoriatic arthritis , Reumatismo: Vol. 55 No. 3 (2003)
- D. Bonanno, R. Fedele, P. Minciullo, P. Quattrocchi, B. Ferlazzo, Idiopathic hypereosinophilic syndrome associated with rheumatoid arthritis A case report , Reumatismo: Vol. 55 No. 3 (2003)
- M. Padovan, M. Govoni, F. Trotta, Semeiology of “early arthritis” , Reumatismo: Vol. 55 No. 3 (2003)
<< < 16 17 18 19 20 21 22 23 24 25 > >>
You may also start an advanced similarity search for this article.
